(NASDAQ: KNSA) Kiniksa Pharmaceuticals International's forecast annual revenue growth rate of 20.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Kiniksa Pharmaceuticals International's revenue in 2025 is $481,166,000.On average, 3 Wall Street analysts forecast KNSA's revenue for 2025 to be $43,798,123,016, with the lowest KNSA revenue forecast at $43,551,991,944, and the highest KNSA revenue forecast at $44,089,058,261. On average, 3 Wall Street analysts forecast KNSA's revenue for 2026 to be $53,217,726,233, with the lowest KNSA revenue forecast at $52,181,538,502, and the highest KNSA revenue forecast at $54,122,566,224.
In 2027, KNSA is forecast to generate $61,919,514,048 in revenue, with the lowest revenue forecast at $59,583,713,394 and the highest revenue forecast at $63,346,826,162.